(lp0
S'Epizyme Inc.  Breaks into New 52-Week High on March 15 Session Equities.com - 12 hours ago Shares of Epizyme Inc.  broke into a new 52-week high yesterday, hitting a peak of $17.35. Shares closed at $16.95 after opening at $16.45 for a move of 3.35%.EPS Projection Of Epizyme, Inc.  At $-0.6625 - RealistInvestor.comEpizyme, Inc.  Broker Price Targets For The Coming Week - Fiscal Standard'
p1
aS'Epizyme President of Research and Chief Scientific Officer, Robert Copeland ... GlobeNewswire  - Mar 9, 2017 CAMBRIDGE, Mass., March 09, 2017  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that President of Research and Chief Scientific Officer, Robert&nbsp;...Epizyme  Reports A Narrower Q4 Loss - Yahoo FinanceEPIZYME, INC.  Files An 8-K Results of Operations and Financial ... - Market Exclusive'
p2
aS'Epizyme Earns $6 Million Milestone Payment from GlaxoSmithKline for Initiation ... GlobeNewswire  - Sep 15, 2016 CAMBRIDGE, Mass., Sept. 15, 2016  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, today announced it has earned a $6 million milestone payment from&nbsp;...'
p3
aS'Epizyme Inc.  Soars 9.87% on March 10 Equities.com - Mar 10, 2017 Epizyme Inc.  had a good day on the market for Friday March 10 as shares jumped 9.87% to close at $16.70. About 1.01 million shares traded hands on 6,365 trades for the day, compared with an average daily volume of 384,603 shares out of a total&nbsp;...'
p4
aS'Epizyme Announces Presentation at JP Morgan 35th Annual Healthcare Conference GlobeNewswire  - Jan 3, 2017 CAMBRIDGE, Mass., Jan. 03, 2017  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that Robert Bazemore, chief executive officer of Epizyme, will&nbsp;...'
p5
aS'Epizyme Establishes Collaboration with Foundation Medicine to Support ... GlobeNewswire  - Sep 21, 2016 CAMBRIDGE, Mass., Sept. 21, 2016  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, today announced that the Company has entered into a collaboration agreement&nbsp;...'
p6
aS'Epizyme Inc.  Soars 9.22% on February 02 Equities.com - Feb 2, 2017 Epizyme Inc.  had a good day on the market for Thursday February 02 as shares jumped 9.22% to close at $11.25. About 842,606 shares traded hands on 5,582 trades for the day, compared with an average daily volume of 311,298 shares out of a&nbsp;...Brokers Change Their Target Price On Epizyme, Inc.  - Fiscal Standard'
p7
aS'Epizyme Inc.  Moves Lower on Volume Spike for March 01 Equities.com - Mar 1, 2017 Epizyme Inc.  traded on unusually high volume on Mar. 01, as the stock lost 1.76% to close at $13.95. On the day, Epizyme Inc. saw 823,383 shares trade hands on 5,248 trades. Considering that the stock averages only a daily volume of 407,069&nbsp;...Floating Price Update: Epizyme, Inc.  - Is storiesEPS Projection Of Epizyme, Inc.  At $-0.665 - RealistInvestor.com'
p8
aS'Epizyme Appoints Pamela Strode as Vice President, Regulatory Affairs and ... GlobeNewswire  - Sep 29, 2016 CAMBRIDGE, Mass., Sept. 29, 2016  -- Epizyme, Inc. , a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that it has appointed Pamela Strode to the&nbsp;...'
p9
aS"Epizyme Provides Update on Execution of Clinical Program and Reports Third ... GlobeNewswire  - Nov 3, 2016 CAMBRIDGE, Mass., Nov. 03, 2016  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today recapped recent progress of the Company's clinical-stage programs and&nbsp;..."
p10
a.